Clinical trials: Primary Sclerosing Cholangitis
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital
Primary Sclerosing Cholangitis, Biliary Atresia
Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The goals of the proposed work are two fold: Firstly, to see if the antibiotic vancomycin may be used for the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC).
- Trial name
- PSC (NCT01322386)
- Testing
- Vancomycin
- Volunteers
- 32 people
- Sponsor
- Stanford University
Primary Sclerosing Cholangitis, Biliary Atresia
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism.
- Trial name
- NCT02137668
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sacramento Pediatric Gastroenterology
Retroperitoneal Fibrosis, Autoimmune Pancreatitis
Rituximab in IgG4-RD: A Phase 1-2 Trial
The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.
- Conditions
- Retroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis, Pseudotumor
- Trial name
- NCT01584388
- Testing
- Rituximab
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Secondary Sclerosing Cholangitis
Secondary Sclerosing Cholangitis in Critically Ill Patients
SSC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. The investigators hypothesize that genetic variants of biliary transporter genes are frequent in patients with SSC-CIP.
- Trial name
- SSC-CIP (NCT02545309)
- Where
- Austria
- Volunteers
- 140 people
- Sponsor
- Medical University of Graz
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis
PSC is a chronic cholestatic disorder. The investigators intend to study some telomere parameters and telomere length in order to predict a premalignant state.
- Trial name
- NCT02247622
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
- Trial name
- NCT02808312
- Testing
- Cilofexor
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Inflammatory Bowel Disease (IBD), Primary Sclerosing Cholangitis (PSC)
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
This study aims to determine the performance of the Exact IBD-ACRN surveillance test to detect colorectal cancer (CRC) and colorectal neoplasia in patients with inflammatory bowel disease (IBD).
- Conditions
- Inflammatory Bowel Disease (IBD), Primary Sclerosing Cholangitis (PSC), Colorectal Neoplasms, Colorectal Cancer
- Trial name
- OCEANIA (NCT01819766)
- Where
- 26 sites in United States, Canada
- Volunteers
- 440 people
- Sponsor
- Exact Sciences Corporation
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Primary Sclerosing Cholangitis (PSC)
Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis
The cause of PSC is unknown.To date, there is no treatment besides liver transplantation proven to improve PSC prognosis. However, there is a clear medical unmet need yet for patients with PSC, due to risks and complications of…
- Trial name
- NCT06975150
- Testing
- HK-660S 100mg, HK-660S 200mg
- Volunteers
- 105 people
- Sponsor
- CuromeBiosciences
Primary Sclerosing Cholangitis (PSC)
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159
The whole study includes 2 parts. Both the SAD study and MAD study are randomized, double-blinded, and placebo-controlled studies, conducted in healthy subjects, to assess the safety, tolerability, pharmacokinetics, and…
- Trial name
- NCT05082779
- Testing
- CS0159
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Cascade Pharmaceuticals, Inc
Primary Sclerosing Cholangitis (PSC)
Genomics of Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC) is a progressive liver disorder of unknown cause. Current evidence suggests that genes, the genetic material we inherit from our parents, in combination with environmental factors, likely play…
- Trial name
- NCT01161992
- Testing
- Genetic Analysis
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Mayo Clinic
Primary Sclerosing Cholangitis
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease.
- Trial name
- NCT04685200
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary Sclerosing Cholangitis (PSC)
Endoscopy and Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC) is a chronic, cholestatic, immune-mediated liver disease characterized by segmental inflammation, fibrosis and destruction of the intra and / or extrahepatic biliary tree.
- Trial name
- NCT06686810
- Testing
- Endoscopic Retrogradade CholangioPancreatography (ERCP)
- Where
- Italy
- Volunteers
- 118 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Primary Sclerosing Cholangitis
Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is a chronic progressive biliary disease that affects approximately 1200 patients in the Netherlands and around 80,000 in the Western world.
- Trial name
- CATCH-IT (NCT05462093)
- Testing
- Liver Multiscan sequences, Liver Multiscan analysis, MRCP+
- Volunteers
- 200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Primary Sclerosing Cholangitis, Cholestasis
Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy
The objectives of this study are to evaluate the effect of bezafibrate treatment compared to placebo on efficacy and safety in patients with primary sclerosing cholangitis (PSC) and persistent cholestasis despite ursodeoxycholic…
- Trial name
- BEZASCLER (NCT04309773)
- Testing
- Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Sclerosing Cholangitis, Cholangitis
A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
Randomized, double-blind, active-controlled, parallel-group study of HTD1801 in adolescents.
- Conditions
- Primary Sclerosing Cholangitis, Cholangitis, Cholangitis, Sclerosing, Bile Duct Diseases
- Trial name
- NCT03678480
- Testing
- HTD1801, Ursodeoxycholic Acid
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Quantitative MRCP
This study aims to determine the repeatability and reproducibility of Quantitative Magnetic Resonance Cholangiopancreatography (MRCP).
- Conditions
- Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Gallstones, Liver Diseases
- Trial name
- NCT03809559
- Testing
- MRCP+
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Perspectum
Primary Sclerosing Cholangitis
Probiotics in Patients With Primary Sclerosing Cholangitis
PSC is a progressive liver disease without effective medical treatment. There is often co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to benefit patients with ulcerative colitis.
- Trial name
- NCT00161148
- Testing
- Probiotics
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- UMC Utrecht
Sclerosing Cholangitis
Clinical Utility of the Spyglass System in Primary Sclerosing Cholangitis (PSC)
This study aim to prospectively evaluate the clinical utility of Spyglass in sclerosing cholangitis patients undergoing endoscopic retrograde cholangiopancreaticography (ERCP).
- Trial name
- NCT01556555
- Where
- Sweden
- Volunteers
- 46 people
- Sponsor
- Karolinska University Hospital